FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141586557> ?p ?o ?g. }

• W2141586557 endingPage "954" @default.
• W2141586557 startingPage "946" @default.
• W2141586557 abstract "Integrin αvβ3 plays a significant role in angiogenesis during tumor growth and metastasis, and is a receptor for the extracellular matrix proteins with the exposed arginine(R)-glycine(G)-aspartic acid(D) tripeptide sequence. The over-expression of integrin αvβ3 during tumor growth and metastasis presents an interesting molecular target for both early detection and treatment of rapidly growing solid tumors. Considering the advantages of 177Lu for targeted radiotherapy and enhanced tumor targeting capability of cyclic RGD peptide dimer, an attempt has been made to optimize the protocol for the preparation of clinical dose of 177Lu labeled DOTA-E[c(RGDfK)]2 (E = Glutamic acid, f = phenyl alanine, K = lysine) as a potential agent for targeted tumor therapy. 177Lu was produced by thermal neutron bombardment on enriched Lu2O3 (82% in 176Lu) target at a flux of 1 × 1014 n/cm2.s for 21 d. Therapeutic dose of 177Lu-DOTA-E[c(RGDfK)]2 (7.4 GBq) was prepared by adding the aqueous solution of the ligand and 177LuCl3 to 0.1 M NH4OAC buffer containing gentisic acid and incubating the reaction mixture at 90 °C for 30 min. The yield and radiochemical purity of the complex was determined by HPLC technique. Parameters, such as, ligand-to-metal ratio, pH of the reaction mixture, incubation time and temperature were varied using tracer quantity of 177Lu (37 MBq) in order to arrive at the optimized protocol for the preparation of clinical dose. Biological behavior of the radiotracer prepared was studied in C57/BL6 mice bearing melanoma tumors. 177Lu was produced with a specific activity of 950 ± 50 GBq/mg (25.7 ± 1.4 Ci/mg) and radionuclidic purity of 99.98%. A careful optimization of several parameters showed that 177Lu-DOTA-E[c(RGDfK)]2 could be prepared with adequately high radiochemical purity using a ligand-to-metal ratio ~ 2. Based on these studies therapeutic dose of the agent with 7.4 GBq of 177Lu was formulated in ~ 63 GBq/μM specific activity with high yield (98.2 ± 0.7%), radiochemical purity and in vitro stability. Biodistribution studies carried out in C57/BL6 mice bearing melanoma tumors revealed specific accumulation of the radiolabeled conjugate in tumor (3.80 ± 0.55% ID/g at 30 min p.i.) with high tumor to blood and tumor to muscle ratios. However, the uptake of the radiotracer in the tumor was found to be reduced to 1.51 ± 0.32 %ID/g at 72 h p.i. The present work successfully demonstrates the formulation of an optimized protocol for the preparation of 177Lu labeled DOTA-E[c(RGDfK)]2 for PRRT applications using 177Lu produced by direct neutron activation in a medium flux research reactor." @default.
• W2141586557 created "2016-06-24" @default.
• W2141586557 creator A5024993863 @default.
• W2141586557 creator A5027895380 @default.
• W2141586557 creator A5031322337 @default.
• W2141586557 creator A5088582248 @default.
• W2141586557 date "2013-10-01" @default.
• W2141586557 modified "2023-09-23" @default.
• W2141586557 title "Tracer level radiochemistry to clinical dose preparation of 177Lu-labeled cyclic RGD peptide dimer" @default.
• W2141586557 cites W1968173729 @default.
• W2141586557 cites W1986818072 @default.
• W2141586557 cites W1990506324 @default.
• W2141586557 cites W1996489028 @default.
• W2141586557 cites W2000799481 @default.
• W2141586557 cites W2001753204 @default.
• W2141586557 cites W2004182520 @default.
• W2141586557 cites W2008481106 @default.
• W2141586557 cites W2008769552 @default.
• W2141586557 cites W2009510043 @default.
• W2141586557 cites W2012223968 @default.
• W2141586557 cites W2016356824 @default.
• W2141586557 cites W2020318021 @default.
• W2141586557 cites W2024595947 @default.
• W2141586557 cites W2030811592 @default.
• W2141586557 cites W2040573057 @default.
• W2141586557 cites W2043720960 @default.
• W2141586557 cites W2048598450 @default.
• W2141586557 cites W2061335345 @default.
• W2141586557 cites W2061964244 @default.
• W2141586557 cites W2062711801 @default.
• W2141586557 cites W2065246138 @default.
• W2141586557 cites W2074707269 @default.
• W2141586557 cites W2083916521 @default.
• W2141586557 cites W2084238159 @default.
• W2141586557 cites W2088056286 @default.
• W2141586557 cites W2108713158 @default.
• W2141586557 cites W2112368270 @default.
• W2141586557 cites W2120434059 @default.
• W2141586557 cites W2140859605 @default.
• W2141586557 cites W2145270911 @default.
• W2141586557 cites W2187193321 @default.
• W2141586557 cites W2316381016 @default.
• W2141586557 cites W4238973235 @default.
• W2141586557 doi "https://doi.org/10.1016/j.nucmedbio.2013.05.011" @default.
• W2141586557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23850487" @default.
• W2141586557 hasPublicationYear "2013" @default.
• W2141586557 type Work @default.
• W2141586557 sameAs 2141586557 @default.
• W2141586557 citedByCount "16" @default.
• W2141586557 countsByYear W21415865572014 @default.
• W2141586557 countsByYear W21415865572015 @default.
• W2141586557 countsByYear W21415865572016 @default.
• W2141586557 countsByYear W21415865572017 @default.
• W2141586557 countsByYear W21415865572019 @default.
• W2141586557 countsByYear W21415865572020 @default.
• W2141586557 countsByYear W21415865572021 @default.
• W2141586557 countsByYear W21415865572022 @default.
• W2141586557 crossrefType "journal-article" @default.
• W2141586557 hasAuthorship W2141586557A5024993863 @default.
• W2141586557 hasAuthorship W2141586557A5027895380 @default.
• W2141586557 hasAuthorship W2141586557A5031322337 @default.
• W2141586557 hasAuthorship W2141586557A5088582248 @default.
• W2141586557 hasConcept C116569031 @default.
• W2141586557 hasConcept C167392928 @default.
• W2141586557 hasConcept C170493617 @default.
• W2141586557 hasConcept C177322064 @default.
• W2141586557 hasConcept C178790620 @default.
• W2141586557 hasConcept C185592680 @default.
• W2141586557 hasConcept C202751555 @default.
• W2141586557 hasConcept C2777807558 @default.
• W2141586557 hasConcept C2779281246 @default.
• W2141586557 hasConcept C2779546866 @default.
• W2141586557 hasConcept C55493867 @default.
• W2141586557 hasConcept C71240020 @default.
• W2141586557 hasConceptScore W2141586557C116569031 @default.
• W2141586557 hasConceptScore W2141586557C167392928 @default.
• W2141586557 hasConceptScore W2141586557C170493617 @default.
• W2141586557 hasConceptScore W2141586557C177322064 @default.
• W2141586557 hasConceptScore W2141586557C178790620 @default.
• W2141586557 hasConceptScore W2141586557C185592680 @default.
• W2141586557 hasConceptScore W2141586557C202751555 @default.
• W2141586557 hasConceptScore W2141586557C2777807558 @default.
• W2141586557 hasConceptScore W2141586557C2779281246 @default.
• W2141586557 hasConceptScore W2141586557C2779546866 @default.
• W2141586557 hasConceptScore W2141586557C55493867 @default.
• W2141586557 hasConceptScore W2141586557C71240020 @default.
• W2141586557 hasIssue "7" @default.
• W2141586557 hasLocation W21415865571 @default.
• W2141586557 hasLocation W21415865572 @default.
• W2141586557 hasOpenAccess W2141586557 @default.
• W2141586557 hasPrimaryLocation W21415865571 @default.
• W2141586557 hasRelatedWork W1970775527 @default.
• W2141586557 hasRelatedWork W1980377213 @default.
• W2141586557 hasRelatedWork W2073421986 @default.
• W2141586557 hasRelatedWork W2097240451 @default.
• W2141586557 hasRelatedWork W2467234707 @default.
• W2141586557 hasRelatedWork W2764909720 @default.
• W2141586557 hasRelatedWork W2950036561 @default.

• next